These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 38992911)

  • 1. Relevance of plasma lenvatinib concentrations and endogenous urinary cytochrome P450 3A activity biomarkers in clinical practice.
    Kumondai M; Ogawa R; Hayashi N; Ishida Y; Oshikiri H; Sato Y; Kikuchi M; Sato Y; Sato T; Maekawa M; Mano N
    Pharmacol Res Perspect; 2024 Aug; 12(4):e1241. PubMed ID: 38992911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetic-pharmacodynamic modeling of serum biomarkers as predictors of tumor dynamics following lenvatinib treatment in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC).
    Majid O; Hayato S; Sreerama Reddy SH; Lalovic B; Hihara T; Hoshi T; Funahashi Y; Aluri J; Takenaka O; Yasuda S; Hussein Z
    CPT Pharmacometrics Syst Pharmacol; 2024 Jun; 13(6):954-969. PubMed ID: 38528813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer.
    Ozeki T; Nagahama M; Fujita K; Suzuki A; Sugino K; Ito K; Miura M
    Sci Rep; 2019 Apr; 9(1):5404. PubMed ID: 30931962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of hepatic impairment on lenvatinib pharmacokinetics following single-dose oral administration.
    Shumaker R; Aluri J; Fan J; Martinez G; Pentikis H; Ren M
    J Clin Pharmacol; 2015 Mar; 55(3):317-27. PubMed ID: 25204557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of lenvatinib plasma concentration with clinical efficacy and adverse events in patients with hepatocellular carcinoma.
    Hata K; Suetsugu K; Egashira N; Makihara Y; Itoh S; Yoshizumi T; Tanaka M; Kohjima M; Watanabe H; Masuda S; Ieiri I
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):803-813. PubMed ID: 33095285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of lenvatinib trough plasma concentrations with lenvatinib-induced toxicities in Japanese patients with thyroid cancer.
    Nagahama M; Ozeki T; Suzuki A; Sugino K; Niioka T; Ito K; Miura M
    Med Oncol; 2019 Mar; 36(5):39. PubMed ID: 30919115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses.
    Tamai T; Hayato S; Hojo S; Suzuki T; Okusaka T; Ikeda K; Kumada H
    J Clin Pharmacol; 2017 Sep; 57(9):1138-1147. PubMed ID: 28561918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification of cortisol and 6 beta-hydroxycortisol in human urine by LC-MS/MS, and gender-specific evaluation of the metabolic ratio as biomarker of CYP3A activity.
    Lutz U; Bittner N; Ufer M; Lutz WK
    J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Jan; 878(1):97-101. PubMed ID: 19959402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol.
    Ushiama H; Echizen H; Nachi S; Ohnishi A
    Clin Pharmacol Ther; 2002 Jul; 72(1):33-43. PubMed ID: 12152002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Vivo Cytochrome P450 3A Isoenzyme Activity and Pharmacokinetics of Imatinib in Relation to Therapeutic Outcome in Patients With Chronic Myeloid Leukemia.
    Skoglund K; Richter J; Olsson-Strömberg U; Bergquist J; Aluthgedara W; Ubhayasekera SJ; Vikingsson S; Svedberg A; Söderlund S; Sandstedt A; Johnsson A; Aagesen J; Alsenhed J; Hägg S; Peterson C; Lotfi K; Gréen H
    Ther Drug Monit; 2016 Apr; 38(2):230-8. PubMed ID: 26693810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenvatinib Long-Term Responses in Refractory Thyroid Cancer: Our Mono-Institutional Real-Life Experience with the Multidisciplinary Approach and Review of Literature.
    Denaro N; Latina A; Cesario F; Bramardi F; Corrado L; Borretta G; Merlano MC
    Oncology; 2019; 97(4):206-210. PubMed ID: 31390629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults.
    Shumaker RC; Aluri J; Fan J; Martinez G; Thompson GA; Ren M
    Clin Drug Investig; 2014 Sep; 34(9):651-9. PubMed ID: 25022720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib.
    Ando Y; Kawaoka T; Suehiro Y; Yamaoka K; Kosaka Y; Uchikawa S; Kodama K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Mori N; Takaki S; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Moriya T; Naeshiro N; Azakami T; Takahashi S; Imamura M; Chayama K; Aikata H
    Oncology; 2020; 98(11):787-797. PubMed ID: 32882687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis.
    Hiraoka A; Kumada T; Kariyama K; Takaguchi K; Atsukawa M; Itobayashi E; Tsuji K; Tajiri K; Hirooka M; Shimada N; Shibata H; Ishikawa T; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Itokawa N; Imai M; Joko K; Hiasa Y; Michitaka K;
    Cancer Med; 2019 Jan; 8(1):137-146. PubMed ID: 30575325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution of Exogenous and Endogenous CYP3A Markers and Related Factors in Healthy Males and Females.
    Lee J; Kim AH; Yi S; Lee S; Yoon SH; Yu KS; Jang IJ; Cho JY
    AAPS J; 2017 Jul; 19(4):1196-1204. PubMed ID: 28523515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1β-Hydroxydeoxycholic Acid as an Endogenous Biomarker in Human Plasma for Assessment of CYP3A Clinical Drug-Drug Interaction Potential.
    Xue Y; Wang L; Huo R; Chen M; Melo B; Dingley K; Gaudy A; Shen JX
    Drug Metab Dispos; 2024 Aug; 52(9):966-974. PubMed ID: 38991779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and excretion of (14)C-lenvatinib in patients with advanced solid tumors or lymphomas.
    Dubbelman AC; Rosing H; Nijenhuis C; Huitema AD; Mergui-Roelvink M; Gupta A; Verbel D; Thompson G; Shumaker R; Schellens JH; Beijnen JH
    Invest New Drugs; 2015 Feb; 33(1):233-40. PubMed ID: 25377392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Hepatic Cytochrome P450 3A Activity Using Metabolic Markers in Patients with Renal Impairment.
    Kim AH; Yoon S; Lee Y; Lee J; Bae E; Lee H; Kim DK; Lee S; Yu KS; Jang IJ; Cho JY
    J Korean Med Sci; 2018 Dec; 33(53):e298. PubMed ID: 30595680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma 6β-hydroxycortisol to cortisol ratio as a less invasive cytochrome P450 3A phenotyping method.
    Hirano R; Yokokawa A; Furihata T; Shibasaki H
    Br J Clin Pharmacol; 2024 Apr; 90(4):1016-1026. PubMed ID: 38102865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment.
    Parra-Guillen ZP; Berger PB; Haschke M; Donzelli M; Winogradova D; Pfister B; Früh M; Gillessen S; Krähenbühl S; Kloft C; Joerger M
    Basic Clin Pharmacol Toxicol; 2017 Oct; 121(4):309-315. PubMed ID: 28444958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.